Welcome to our dedicated page for Positron SEC filings (Ticker: POSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Positron Corporation (POSC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as an SEC reporting issuer. Positron has stated that it filed a Form 10 registration statement with the U.S. Securities and Exchange Commission and is subject to the reporting requirements of the Securities Exchange Act of 1934, which means investors can review periodic and current reports to better understand the business.
Through this page, users can monitor current reports on Form 8-K, where Positron discloses material events. Recent 8-K filings include information about unregistered sales of equity securities under a subscription agreement, as well as a change in the company’s independent registered public accounting firm and the engagement of a new auditor to examine its financial statements and review interim periods.
As Positron progresses as a reporting company, this page will also surface annual reports on Form 10-K and quarterly reports on Form 10-Q, once filed, which are expected to cover areas such as its PET and PET-CT imaging systems, clinical services, technology partnerships, and capital structure. These filings can help readers analyze how the company describes its molecular imaging business, risk factors, and financial condition.
Stock Titan enhances access to POSC filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of capital raises, significant agreements, or auditor changes, so users can quickly understand the context of each filing. In addition, investors can use this page to track registration details for Positron’s common stock on the OTC Markets and review historical filings as part of their due diligence on POSC.
Positron Corporation filed its annual report detailing continued losses and going concern risk. The medical imaging company reported 2025 revenue of $461,452, down from $587,500 in 2024, while net loss widened to $10,603,392 and accumulated deficit reached $144,937,079.
The report states there is substantial doubt about Positron’s ability to continue as a going concern, as operations are not expected to generate sufficient cash to meet obligations without additional financing. At December 31, 2025, cash was $2,520,466 with current liabilities of $2,402,141 and working capital of $937,045.
To fund operations, Positron raised $10,000,000 from common stock sales in 2025 but also repurchased 4,000,000 shares for $2,500,000. It granted 5,150,000 fully vested stock options at $1.48 per share to management and highlighted plans to commercialize its Affinity PET-CT system while relying heavily on future capital-raising efforts.
Positron Corporation disclosed that on December 23, 2025 it entered into a Subscription Agreement with a single investor to sell 1,333,333 shares of its common stock for an aggregate purchase price of $2,000,000. The transaction was completed without the use of a placement agent or finder, meaning the company dealt directly with the investor.
The shares were issued in a private transaction not registered under the Securities Act of 1933, relying on the Regulation S exemption. This issuance represents new equity capital for Positron and results in additional common shares outstanding. The company also filed the Subscription Agreement and a related press release as exhibits.
Positron Corporation reports a change in its independent auditor. Freed Maxick P.C. resigned as the company’s independent registered public accounting firm effective October 31, 2025. On December 10, 2025, the company appointed Salberg & Company, P.A. as its new independent registered public accounting firm.
Salberg has been engaged to audit Positron Corporation’s financial statements for the year ended December 31, 2025 and to review interim financial statements for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026. The company states that during the two most recent fiscal years and through December 10, 2025, it did not consult with Salberg on the application of accounting principles, the type of audit opinion that might be issued, or on any matter involving a “disagreement” or “reportable event” as defined in SEC rules.